Comparing the current results to its competitors, Catheter Precision Inc reported Revenue increase in the 2 quarter 2026 by 380.66 % year on year. The sales growth was above Catheter Precision Inc 's competitors' average revenue growth of 11.08 %, achieved in the same quarter.
Catheter Precision Inc 's Comment on Competition and Industry Peers
The company operates in the medical device industry, focusing on the cardiac electrophysiology sector. It competes with established medical device companies including Medtronic, Plc., Abbott Laboratories, Biosense-Webster (J&J), and Boston Scientific Corp. Specific competitors to the company's LockeT product include Abbott's Perclose device, Haemonetic's VASCADE device, and Inari Medical's FlowStasis device. Key competitive factors in the market include product performance, reliability, manufacturing cost, and customer support.
September 10, 2025
In a significant leap forward for the cardiac electrophysiology landscape, Catheter Precision, Inc. (NYSE/American: VTAK), has announced noteworthy advancements that underscore its growing influence in the European medical devices market. Headquartered in Fort Mill, South Carolina, Catheter Precision has emerged as a key player in developing state-of-the-art solutions targeting the intricacies of cardiac care. Its recent successes, including securing pivotal purchase orders and reporting remarkable sales growth for its flagship products, mark a promising trajectory for the company.On September 10, 2025, Catheter Precision disclosed its triumph in a competitive tender process, culminating in its first purchas...
April 14, 2025
As the medical technology landscape continues to evolve, companies in the space are constantly pushing the boundaries to create innovative solutions that address both existing and emerging healthcare challenges. Catheter Precision, Inc. (VTAK NYSEAmerican), a South Carolina-based company that is steadily making waves in the cardiac electrophysiology market, stands testament to this relentless pursuit of advancement, albeit with some financial hurdles to overcome.On April 14, 2025, Catheter Precision announced a significant milestone: the company had received a notice of allowance from the United States Patent and Trademark Office for its first US patent for the LockeT product line. This development underscor...
Boston Scientific Corporations business model centers on creating innovative medical devices for diverse specialties, aimed at addressing unmet medical needs and enhancing patient outcomes. The company sells its products to healthcare professionals and hospitals globally, supported by robust sales and distribution networks. It prioritizes research and development to continually introduce new technologies and solutions.
Baxter International Inc is a global healthcare company that specializes in providing a wide range of medical products and services. They operate through various business segments including Pharmaceuticals, Medical Products, and Renal Care, offering solutions for hospitals, clinics, and home-based healthcare settings.
Atricure Inc is a medical device company that focuses on developing, manufacturing, and selling innovative surgical solutions for the treatment of cardiac arrhythmias and other heart-related conditions.
Sources:
Catheter Precision Inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: publicly traded companies.
For your research, we’ve provided 10 tables on Catheter Precision Inc versus competitors, including market share analysis.
You can find them in the navigation menu under Competition.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
